Spotlight -

Drug Development|

Quality Systems

News|Articles|March 28, 2013

Standardization, Modular Unit Operations, and Global Deployment

Pär Almhem, President of ModWave and ModularPartners discusses modularization and his upcoming presentation at Interphex

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance. Subscribe to Pharmaceutical Technology and never miss an industry breakthrough.

Related Content

Pharma Fundamentals: Risks and Regulations for Hold Times in Biopharmaceuticals

ByRobert Dream,Susan Haigney

August 27th 2026

3D bioprinting is the utilization of 3D printing to combine cells, growth biomaterials to make biomedical parts | Image Credit: ©luchschenF -stock.adobe.com

3D Printing Revolutionizing Tissue Engineering and Regenerative Medicine in Europe

ByCheryl Barton

August 26th 2026

McKesson Corporation agreed to acquire Precision Medicine Group, adding a variety of drug development and commercialization capabilities.

What the McKesson-Precision Medicine Deal Signals for Trial Sponsors

ByZachary Zubulake

August 25th 2026

n-nitrosodimethylamine molecular structure, 3d model molecule, dimethylnitrosamine, structural chemical formula view from a microscope | Image Credit: ©Сергей Шиманович -stock.adobe.com

From Detection to Prediction: Modern Analytical Approaches for Nitrosamine Risk

ByChris Williams

August 24th 2026

Genglycos (pariglasgene brecaparvovec-opnr), a gene therapy for adult and pediatric patients eight years and older with glycogen storage disease type Ia recieved accelerated approval from the FDA.

GSDIa Gene Therapy Approval Signals New Path for Rare Disease Manufacturing

ByZachary Zubulake

August 20th 2026

Trending on Pharmaceutical Technology

Rasonque's 60% Survival Benefit: What It Means for Oncology Pipelines

What the McKesson-Precision Medicine Deal Signals for Trial Sponsors

3D Printing Revolutionizing Tissue Engineering and Regenerative Medicine in Europe

GSK's Jemperli Rectal Cancer Filing Signals Biologics Capacity Shift

Can Predictive Modelling Fix Fragmented Pharma Development Data?